Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation

NCT00457067 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

NIH

Sponsor class

Conditions

Telangiectasia

Interventions

DRUG: Ranibizumab

Sponsor

National Eye Institute (NEI)